MAPK1 and Alzheimer disease: XSBO treatment resulted in decreased expression of phosphorylated P38 (p-P38) and phosphorylated ERK (p-ERK) (Figure 6h-i), suggesting that the therapeutic efficacy of XSBO in AD may be attributed to its ability to mitigate inflammation through inhibition of the MAPK pathway.